EU Panel Backs Adjuvant Nivolumab for Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease
Source: OncLive